Drugs Containing Excipient (Inactive Ingredient) AMINOPHYLLINE

« Back to Dashboard

Generic drugs containing AMINOPHYLLINE excipient

Company	Ingredient	NDC	Excipient
Proficient Rx LP	carvedilol	63187-424	AMINOPHYLLINE
Proficient Rx LP	carvedilol	63187-570	AMINOPHYLLINE

Aminophylline Market Dynamics, Patent Position, and Financial Trajectory

Last updated: October 21, 2026

Aminophylline is not a pharmaceutical excipient. It is an active pharmaceutical ingredient, or API, comprising theophylline complexed with ethylenediamine. Its commercial market is mature, low-growth, and fragmented. Demand is concentrated in generic injectable products and selected oral formulations, while clinical substitution by inhaled bronchodilators and corticosteroids continues to reduce use in developed markets.

No reliable public source reports a standalone global revenue figure for aminophylline. Public-company filings generally aggregate aminophylline within broader generic injectables or respiratory portfolios. The financial trajectory is therefore best assessed through clinical utilization, generic competition, manufacturing economics, regulatory status, and substitution risk.

What is aminophylline and how is it used?

Aminophylline is the ethylenediamine salt of theophylline. Ethylenediamine increases theophylline’s aqueous solubility, which supports injectable formulations. The drug produces bronchodilation through phosphodiesterase inhibition and adenosine-receptor antagonism.

Attribute	Aminophylline
Active component	Theophylline
Salt or complex	Theophylline ethylenediamine
Primary dosage forms	Injectable solution; tablets and extended-release oral products
Common strengths	25 mg/mL injection; multiple oral strengths
Therapeutic area	Asthma and chronic obstructive pulmonary disease
Regulatory category	Prescription drug
Patent status	Legacy molecule with no meaningful composition-of-matter exclusivity
Biosimilar status	Not applicable
Commercial status	Mature generic market

Aminophylline is used less frequently than in prior decades because it has a narrow therapeutic index, variable pharmacokinetics, and clinically important drug interactions. Modern asthma and COPD treatment relies more heavily on inhaled beta agonists, antimuscarinic agents, inhaled corticosteroids, and combination products. The Global Initiative for Asthma does not recommend routine use of intravenous aminophylline for acute asthma because of limited incremental benefit and toxicity concerns (Global Initiative for Asthma, 2024).

Is aminophylline an excipient or an active pharmaceutical ingredient?

Aminophylline is an API, not an excipient.

An excipient is an inactive component such as sodium chloride, benzyl alcohol, water for injection, lactose, or a tablet binder. Aminophylline provides the pharmacologic effect in the finished product. Product labels identify aminophylline as the active ingredient and list other components separately. The U.S. National Library of Medicine’s DailyMed database identifies aminophylline injection products as prescription drug products containing aminophylline as the active substance (National Library of Medicine, 2024).

This distinction affects market analysis:

• API demand is linked to finished-dose product production.
• Regulatory filings must establish aminophylline identity, strength, purity, and stability.
• Manufacturers compete on API cost, regulatory compliance, supply reliability, and sterile manufacturing capacity.
• The relevant market is the aminophylline API and finished-dose market, not the pharmaceutical-excipient market.

How large is the aminophylline market?

Publicly available filings do not isolate aminophylline revenue as a distinct market category. Market-research estimates that group aminophylline with respiratory APIs, bronchodilators, or generic injectables should not be treated as audited aminophylline sales.

The market is economically small relative to major respiratory products such as albuterol, budesonide, fluticasone, tiotropium, and combination inhalers. Its value is constrained by four factors:

1. The molecule is off-patent and supplied by multiple generic manufacturers.
2. Clinical use has shifted toward inhaled therapies.
3. Aminophylline products generally have low unit prices.
4. Hospital demand is episodic and sensitive to formulary decisions.

The commercial market has two distinct segments:

Segment	Demand profile	Financial outlook
Injectable aminophylline	Emergency departments, hospitals, and selected acute-care settings	Stable to declining volume; occasional supply-driven price increases
Oral aminophylline or theophylline	Chronic respiratory treatment in selected markets	Long-term decline in developed markets
API supply	Contract and merchant API production	Commodity-like pricing with margin tied to compliance and reliability
Emerging-market demand	Lower-cost respiratory treatment where inhaled alternatives are less accessible	More resilient than U.S. and Western European demand

Aminophylline can experience short-term revenue increases during manufacturing interruptions or hospital shortages. Those increases are typically volume or price events rather than evidence of durable market expansion.

What is the financial trajectory for aminophylline?

The base-case trajectory is mature-to-declining revenue, with intermittent volatility caused by supply conditions.

Near-term trajectory

Injectable demand is likely to remain commercially relevant in hospitals that retain aminophylline on formularies. However, routine use is limited by safety concerns and the availability of inhaled therapies. Oral demand is more exposed to substitution and gradual formulary removal.

API manufacturers face pricing pressure from:

• Multiple qualified suppliers.
• Limited product differentiation.
• Low switching costs for generic buyers with approved alternate sources.
• Procurement through tenders and hospital purchasing groups.
• Buyer preference for dual sourcing.

Margins can improve when a supplier has an approved U.S. or European regulatory file, reliable GMP history, and sterile fill-finish capability. The API itself is unlikely to support substantial premium pricing without a supply shortage or a specialized regulatory position.

Medium-term trajectory

The medium-term market is likely to bifurcate. Injectable aminophylline may retain a narrow hospital role, while oral products continue to lose share to inhaled therapies. The strongest commercial positions will belong to manufacturers that combine aminophylline with broader generic injectable portfolios.

A standalone aminophylline strategy has limited growth potential. A portfolio strategy can still generate value through:

• Shared manufacturing infrastructure.
• Common hospital distribution channels.
• Bundled procurement contracts.
• Low incremental development costs.
• Capacity utilization for generic sterile products.

What FDA regulatory status applies to aminophylline?

Aminophylline is regulated as a prescription drug. U.S. products may be marketed under abbreviated new drug applications, legacy approvals, or other approved pathways depending on the product and sponsor.

DailyMed lists U.S. aminophylline injection labeling that describes strengths, dosing, warnings, contraindications, and inactive ingredients. The label emphasizes narrow therapeutic margins, monitoring requirements, and clinically significant interactions (National Library of Medicine, 2024).

Key regulatory considerations include:

• Demonstration of identity and assay for aminophylline.
• Control of theophylline and ethylenediamine content.
• Impurity and degradation-product specifications.
• Sterility and endotoxin controls for injection products.
• Stability of the finished solution.
• Container-closure compatibility.
• Dose uniformity and dissolution for oral products.
• Labeling consistency with approved safety information.

FDA drug-shortage records are commercially relevant because aminophylline injection has historically been exposed to manufacturing and supply interruptions. Shortages can temporarily increase the value of available inventory but also raise regulatory scrutiny and buyer expectations for continuity planning (U.S. Food and Drug Administration, 2024).

What patents protect aminophylline products?

No commercially important composition-of-matter patent protects aminophylline in the United States or other major markets. The active ingredient is an established legacy compound, and generic competition has existed for decades.

Patent category	Current commercial relevance
Aminophylline composition patent	None of practical importance
Theophylline composition patent	Expired
Basic therapeutic-use patent	Expired or commercially irrelevant
Conventional tablet formulation patent	Generally expired
Conventional injectable formulation patent	Generally expired
New formulation or delivery patent	Possible only for a newly developed product
Manufacturing process patent	Limited value unless process-specific and enforceable

The absence of meaningful patent protection does not eliminate all intellectual-property issues. A company could seek protection for a new delivery system, controlled-release profile, combination product, or manufacturing process. Such rights would protect the improvement, not the underlying aminophylline molecule.

When does aminophylline lose exclusivity?

Aminophylline has already lost market exclusivity. Its relevant exclusivity dates are historical rather than prospective.

Generic entrants do not face a meaningful remaining period of innovator exclusivity for conventional aminophylline injection or oral products. Any current commercial barriers arise from regulatory approval, manufacturing qualification, supply reliability, and market access rather than patent expiry.

The practical exclusivity timeline is:

Milestone	Status
Original molecule and salt development	Historical
Original product exclusivity	Expired
Generic entry	Established
Current patent cliff	None
Current market barrier	Regulatory and manufacturing execution

Are there Paragraph IV challenges for aminophylline?

Paragraph IV litigation is not a central current risk for conventional aminophylline products. The drug is already generic, and there is no active branded patent position comparable to newer respiratory products.

A Paragraph IV filing would matter only if a sponsor obtained a later patent covering a particular formulation, dosage regimen, delivery system, or combination. For standard aminophylline injection and established oral products, the commercial issue is approval and supply rather than patent challenge strategy.

The Orange Book remains the relevant U.S. source for listed patents and exclusivity associated with approved drug products. A product-by-product review is necessary because Orange Book status attaches to specific applications, not to the molecule in the abstract (U.S. Food and Drug Administration, 2024).

What is the Orange Book status of aminophylline?

Aminophylline products may appear in FDA approval and labeling databases, but Orange Book interpretation must be conducted by application number and dosage form. The Orange Book does not create market exclusivity for every approved generic product.

For commercial diligence, the relevant questions are:

• Whether the specific reference product has listed patents.
• Whether any listed patent remains unexpired.
• Whether the proposed generic product is therapeutically equivalent.
• Whether the dosage form and strength match the reference product.
• Whether the product has an active ANDA and current marketing status.

For conventional aminophylline products, no broad, active patent estate is expected to block generic entry. Approval status and supply continuity are more important than Orange Book patent risk.

What manufacturing and IP barriers affect aminophylline?

The principal barriers are operational rather than patent-based.

API manufacturing

Aminophylline production requires control of theophylline quality, ethylenediamine stoichiometry, residual solvents, particle characteristics, and impurity profiles. A supplier must maintain validated processes and documentation acceptable to the relevant regulatory authority.

Injectable manufacturing

Sterile production is the more important barrier for commercial entry. Requirements include:

• Validated aseptic processing.
• Sterility assurance.
• Endotoxin control.
• Container-closure integrity.
• Visual inspection.
• Stability data.
• Reliable access to sterile vials, ampoules, or other containers.

This creates a difference between low-cost API supply and marketable injectable product supply. A manufacturer may produce compliant API but lack the sterile manufacturing, regulatory approvals, or distribution network required to compete in hospital tenders.

Which companies are challenging aminophylline?

There is no major branded company currently defending a high-value aminophylline franchise comparable to branded respiratory products. Competition is primarily among generic API suppliers, contract manufacturers, and injectable-drug companies.

The competitive landscape is characterized by:

• Regional generic manufacturers.
• API producers serving multiple respiratory products.
• Contract development and manufacturing organizations.
• Hospital-injection suppliers.
• Local manufacturers in emerging markets.

Public disclosures generally do not identify aminophylline as a material standalone revenue driver. Company-level exposure is therefore best assessed through product catalogs, regulatory databases, shortage records, manufacturing-site data, and tender awards rather than annual-report segment revenue.

What generic launch scenarios exist for aminophylline?

The most credible scenarios are:

Scenario	Likely effect
New low-cost API supplier	Lower procurement prices and greater buyer leverage
New injectable manufacturer	Increased hospital competition; potential price erosion
Existing supplier exits	Temporary shortage and price volatility
Regulatory remediation at a major site	Reduced supply and higher near-term value for approved alternatives
Expanded use in low-resource markets	Modest volume growth without strong pricing power
Continued substitution by inhaled therapies	Long-term decline in developed-market demand

A new entrant can launch more efficiently if it already has an approved sterile platform and hospital sales network. A standalone product launch faces limited market size and substantial commercial pressure.

Is biosimilar risk relevant to aminophylline?

Biosimilar risk is not relevant because aminophylline is a small-molecule drug, not a biologic. The relevant competitive risks are generic entry, therapeutic substitution, procurement pricing, and manufacturing interruption.

The principal substitutes are inhaled short-acting beta agonists, inhaled antimuscarinic agents, inhaled corticosteroids, and combination inhalers. These products compete clinically with aminophylline even when they do not share the same active ingredient.

Are licensing deals or litigation material?

No major publicly disclosed licensing transaction appears to establish a significant standalone aminophylline franchise. Licensing activity, where it occurs, is more likely to involve a broader generic portfolio, regional distribution rights, or contract manufacturing.

Aminophylline also has limited current litigation value. The absence of a live composition patent reduces the likelihood of high-value infringement litigation. Disputes are more likely to involve:

• Product quality.
• Supply contracts.
• Regulatory noncompliance.
• Manufacturing defects.
• Hospital procurement.
• Trademark or labeling matters.

How strong is the aminophylline patent estate?

The patent estate is weak for the base molecule and conventional products. It is stronger only for a genuinely differentiated follow-on product with a valid patent covering formulation, delivery, or use.

Estate component	Strength
Base molecule	Very weak; legacy compound
Conventional injection	Very weak
Conventional oral tablet	Very weak
New controlled-release formulation	Potentially moderate, product-specific
Combination product	Potentially moderate, claim-dependent
Manufacturing process	Narrow and enforcement-dependent
Regulatory exclusivity	Generally unavailable for legacy products

Key Takeaways

• Aminophylline is an API, not a pharmaceutical excipient.
• The molecule and conventional dosage forms are long off-patent.
• No meaningful current patent cliff remains because generic competition is established.
• Injectable demand has greater commercial resilience than oral demand.
• Developed-market use is declining because inhaled therapies offer better clinical positioning.
• The market has no reliable standalone public revenue figure.
• Financial performance depends on hospital tenders, supply continuity, sterile manufacturing, and regional access.
• Patent litigation and Paragraph IV risk are limited.
• Biosimilar risk does not apply.
• The strongest commercial position is a compliant, reliable supplier embedded in a broader generic injectable portfolio.

FAQs

Is aminophylline still manufactured?

Yes. Aminophylline continues to be manufactured for injectable and oral products, although availability varies by country, supplier, and hospital procurement status.

Is aminophylline the same as theophylline?

No. Aminophylline is a theophylline-ethylenediamine complex designed to improve water solubility. The pharmacologically active component is theophylline.

Can aminophylline support a premium API price?

Usually not. Premium pricing is more likely during a shortage or where a supplier has a scarce regulatory approval, validated sterile platform, or unusually strong supply record.

Does aminophylline have a future in respiratory medicine?

Its future is limited to selected acute-care and regional markets. Clinical substitution and safety concerns constrain broad expansion.

What is the main investment risk in aminophylline?

The main risk is structural demand erosion combined with commodity pricing. The principal upside is temporary supply disruption or inclusion in a broader, higher-value generic injectable portfolio.

References

Global Initiative for Asthma. (2024). Global strategy for asthma management and prevention. https://ginasthma.org

National Library of Medicine. (2024). DailyMed: Aminophylline injection prescribing information. https://dailymed.nlm.nih.gov

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

U.S. Food and Drug Administration. (2024). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages

U.S. National Library of Medicine. (2024). PubChem compound summary: Aminophylline. https://pubchem.ncbi.nlm.nih.gov/compound/Aminophylline